{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:30Z","timestamp":1787758230561,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of intravitreal injection (IVI) of bevacizumab (IVB) versus aflibercept (IVA) in premature infants with type 1 prethreshold retinopathy of prematurity (ROP) in the posterior Zone II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was a multicenter, historical cohort of premature newborns diagnosed with type 1 prethreshold ROP in the posterior Zone II, treated with IVB or IVA. Demographic features, complications, and treatment outcomes were then compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy-six patients received aflibercept (the IVA group), and 210 received bevacizumab (the IVB group). The two groups were not significantly different in terms of postmenstrual age (PMA) at the time of ROP diagnosis and other known risk factors for ROP development and progression. All eyes in both the groups responded to IVI; however, recurrence was observed in four eyes (1.9%) in the IVB group and 12 (15.8%) in the IVA group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Recurrence occurred 9.1 \u00b1 0.83 (5\u201312) and 15.5 \u00b1 0.98 (12\u201318) weeks after primary treatment in the IVB and IVA groups, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.000). In the IVA group, retinal vascularization was completed in 38.18 \u00b1 6.5 weeks (21\u201348) after IVI, and it happened in 23.86 \u00b1 9.3 weeks (13\u201360) in the IVB group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009). Furthermore, vascularization reached the peripheral retina in 73.25 \u00b1 6.5 (56\u201384) and 58.75 \u00b1 8.8 (45\u201393) weeks, PMA in the IVA and IVB groups, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). No acute postoperative complications were observed in the treated eyes in either group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study shows that both IVA and IVB are effective and well tolerated for the management of type 1 prethreshold ROP in the posterior Zone II; however, IVA needs a significantly longer time for vascularization completion and has a higher recurrence rate compared with IVB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_193_21","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T15:02:58Z","timestamp":1661439778000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone Ii"],"prefix":"10.4103","volume":"34","author":[{"given":"Amir Eftekhari","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Reza","family":"Niyousha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayyeh","family":"Hazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samad","family":"Safarpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240910","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12968\/ijop.2012.3.1.20","article-title":"Allergic ocular disease: From itchy eyes to visual loss","volume":"3","author":"Johnson","year":"2012","journal-title":"Int J Ophthalmic Pract"},{"key":"R2-13-20240910","doi-asserted-by":"crossref","first-page":"56","DOI":"10.34172\/cjmb.2022.10","article-title":"Efficacy of oral propranolol on the treatment of retinopathy of prematurity","volume":"9","author":"Hosseini","year":"2022","journal-title":"Crescent J Med Biol Sci"},{"key":"R3-13-20240910","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mvr.2007.04.011","article-title":"Retinal and choroidal microangiopathies: Therapeutic opportunities","volume":"74","author":"Afzal","year":"2007","journal-title":"Microvasc Res"},{"key":"R4-13-20240910","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr Rev"},{"key":"R5-13-20240910","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-13-20240910","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/jamaophthalmol.2019.4488","article-title":"Secondary 12-month ocular outcomes of a phase 1 dosing study of bevacizumab for retinopathy of prematurity","volume":"138","author":"Crouch","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R7-13-20240910","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R8-13-20240910","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","article-title":"Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R9-13-20240910","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3928\/01913913-20191104-01","article-title":"Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"57","author":"Ekinci","year":"2020","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R10-13-20240910","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","article-title":"Aflibercept (VEGF Trap-eye): The newest anti-VEGF drug","volume":"96","author":"Stewart","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R11-13-20240910","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-13-20240910","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"R14-13-20240910","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3928\/23258160-20200228-07","article-title":"Functional and morphologic findings at four years after intravitreal bevacizumab or laser for type 1 ROP","volume":"51","author":"Lepore","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R15-13-20240910","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"key":"R16-13-20240910","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R17-13-20240910","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/aos.12049","article-title":"The pathophysiology of retinopathy of prematurity: An update of previous and recent knowledge","volume":"92","author":"Cavallaro","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R18-13-20240910","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/13543784.15.7.779","article-title":"Promising new treatments for neovascular age-related macular degeneration","volume":"15","author":"Michels","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R19-13-20240910","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: A comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyama\u00e7 Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"R20-13-20240910","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"R21-13-20240910","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"R22-13-20240910","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: One-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"R23-13-20240910","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R24-13-20240910","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","article-title":"Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity","volume":"67","author":"Vedantham","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R25-13-20240910","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.ophtha.2010.01.045","article-title":"Ultrasound biomicroscopic configurations of the anterior ocular segment in a population-based study: The Kumejima study","volume":"117","author":"Henzan","year":"2010","journal-title":"Ophthalmology"},{"key":"R26-13-20240910","first-page":"243","article-title":"Hypertension and ischemic stroke after aflibercept for retinopathy of prematurity","volume":"13","author":"Bazvand","year":"2020","journal-title":"Int Med Case Rep J"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_193_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:11:16Z","timestamp":1787757076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_193_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_193_21","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}